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Abstract
Background: Quality of life (QoL) is increasingly used to characterize the impact of disease and the efficacy of 
interventions.
Methods: Prospective cohort study in patients' and proxies' homes with137 patients with dementia (age 52 to 88; 
Mini-Mental Status Examination (MMSE) 3 to 28) and their proxies (age 43 to 90). MMSE, Behave-AD, Geriatric 
Depression Scale (GDS), and Bayer-ADL scale (B-ADL), and the Euroqol (EQ-5D; patient self-rating, proxy self-rating, and 
proxy-rating of patient).
Results: B-ADL impairment and Behave-AD total score increased with dementia severity (Kruskal-Wallis p < 0.001 and 
p = 0.023, respectively). Patients' self-rated QoL and proxies' self-rated QoL were unrelated to dementia severity (p = 
0.148 and p = 0.414, respectively). The difference between patients' self- and proxies'-rating of the patient's QoL 
correlated with the patient's MMSE (Spearman's rho = -0.434; p < 0.001), even if analysis was constrained to patients 
with mild AD (rho = -0.328; p = 0.019). The proxies' rating of the patients QoL was not only correlated with cognitive 
and behavioral symptoms of the patient but also with mood (GDS-score; rho = 0.317; p < 0.001) and cognitive abilities 
(verbal fluency; rho = 0.209; p < 0.018) of the proxy.
Conclusion: Proxies' assessment of the patients' QoL is related to the proxies' health, and the difference of patient's 
and proxie's QoL-rating is correlated with dementia severity even in mild dementia stages. QOL measures use ratings of 
the individual to assess the impact of symptoms and disorders on everyday life. In dementia patients, however, this 
impact is not captured since patients' and proxies' self-assessment of their own QoL do not reflect severity of disease 
whatsoever. Patients' and proxies' influencing variables render the score obtained with generic quality of life 
assessment meaningless in capturing the impact of dementia. Decisions on initiation or discontinuation of treatment 
or allocation of other resources for patients with dementia therefore need not depend on generic assessment of 
quality of life.
Background
Dementia is a frequent disorder in the elderly and its
prevalence increases with age [1]. Due to the demo-
graphic change, the incidence and prevalence of demen-
tia and the number patients and their proxies will
increase in the coming years. This challenges the health
care system to provide effective treatment under the con-
straints of limited economic resources.
The Constitution of the World Health Organization
(WHO) defines health as "A state of complete physical,
mental, and social well-being not merely the absence of
disease. . .". From this definition it is concluded that mea-
surement of health and the effects of health care must
include not only an indication of changes in the fre-
quency and severity of symptoms but also an estimation
of the well-being by measuring the improvement in the
quality of life (QoL) related to health care. QoL is
expected to convey greater meaning and more direct rele-
vance across a wide spectrum of diseases and illnesses
than clinical scales or instruments. Assessment of the
QoL also aims at achieving comparability of the burden of
diseases across the broad array diseases in different spe-
cialties. The WHO summarizes that QoL-instruments
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have many uses, including use in medical practice,
research, audit, and in policy making.
QOL measures use the subjective ratings of the individ-
ual in a variety of areas to assess the impact of symptoms
and disorders on life [2]. By this definition Qol is a subjec-
tive construct, being evaluated and self-reported by the
affected person. In a similar fashion, the influential model
by Lawton characterized five domains pertaining to QoL
for subjects with dementia to comprise the same areas as
for people in general (cognitive functioning, ability to
perform activities of daily living, being able to engage in
meaningful time use, social behavior, and a favorable bal-
ance between positive emotion and absence of negative
emotion) [3]. Similar to the WHO concept this model is
predominantly self-evaluated and self-reported, although
some objective elements, such as perceived contentment
and functional abilities are supplemented. Several instru-
ments have been developed, with the Euroqol being one
of the most widely applied [4-7]
Previous studies on the validity of the patient self-rating
of the quality of life are contradictory. It has been
r e p o r t e d  t h a t  p a t i e n t s  w i t h  A l z h e i m e r ' s  d e m e n t i a  a r e
likely to give overly optimistic ratings of their own mental
capacities, their functions, activities and social relation-
ships [8]. Several studies, however, report that the capa-
bility of self-rating of Qol is not impaired by the severity
of cognitive impairment [9-12].
The use of proxies (e.g relatives or nurses) to measure
QoL has inherent obstacles, such as personality charac-
teristics of the proxy, the nature of the relationship, the
time spent with one another, and the level of impairment.
Frequently, proxy appraisal of the patient's QoL are dispa-
rate to the patients own evaluation [13] but it was inter-
preted that patient- and proxy report may both represent
valid, although differing, perspectives on quality of life
[14]. Discrepancies between ratings of dementia patients'
and their proxies' are reported to be associated with
increased levels of caregiver burden, rather than lower
levels of patients' functioning alone [15,16]. The proxie's
experiences of depression and burden might also nega-
tively affect proxies' assessments of QoL [13].
For this study a large number of patients and proxies
were interviewed in their homes with an extensive battery
comprising the Mini-Mental-Status Examination
(MMSE), the cognitive scale Alzheimer's disease assess-
ment scale (ADAScog), the Behavioral pathology in
Alzheimer's Disease Rating Scale (Behave-AD), the Geri-
atric Depression Scale (GDS), the Bayer-Activities of
daily living scale (B-ADL). It was the goal to assess the
self- and proxy-ratings of QoL and their relation to the
severity of AD.
Methods
The study was performed according to institutional
guidelines and the principles laid out in the Declaration
of Helsinki. Written informed consent was obtained by
patients and proxies.
Patients and Caregivers
The patients and their proxies were recruited from a
cohort of patients applying for a short-term in-patient
treatment at the Alzheimer Therapy Center Bad Aibling.
Initial contact and screening of the eligibility to take part
in the study were made via telephone by a study nurse.
Criteria for inclusion in the study were a diagnosis of
dementia of mixed or Alzheimers type performed by a
general practitioner or neurologist/psychiatrist. Only
patients living in one household with their primary proxy
were included in the study. Current analysis of this ongo-
ing study included all patients with baseline assessment
between September 2008 and December 2009 with a
MMSE score of 3 and above being able to complete the
Geriatric Depression Scale. Six patients had to be
excluded for not being able to complete the GDS scale.
The remaining sample comprises 137 patients with
either AD or mixed dementia (mean age 73.0 ± 6.7 years,
range 52 - 88 years; 69.3% male) and their proxies (mean
age 69.6 ± 7.6 years, range 43 - 90 years; 70.1% female;
98.6% spouses). MMSE scores ranged from 3 - 28 (mean
16.9 ± 6.4). The basic demographic variables are
described in Table 1.
All interviews took place in the domestic surroundings
of the families after explaining the aim of the study and
obtaining informed consent by both the patient and the
proxy. Assessments were carried out by specially trained
research assistants. Patients and proxies were inter-
Table 1: Demographic data of study participants. 
Patients Proxies
n 137 137
Age (median) 74 70
Age (range) 52 - 88 43 - 90
Male (%) 69.3 29.9
Female (%) 30.7 70.1
MMSE (median) 17.0
MMSE (range) 3 - 28
MMSE: Mini-Mental-Status Examination (score 0 - 30).Schiffczyk et al. BMC Neurology 2010, 10:48
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viewed separately to minimize bias and mutual influence
on the responses.
Assessments
Mini-Mental Status Examination (MMSE [17])
The MMSE is the most commonly used instrument to
stage the severity of dementia by assessing cognitive
functions. It comprises tests on orientation, registration,
short-term memory, language use, comprehension, and
basic motor skills. The score ranges from 0 - 30. Com-
monly, the scores on the Mini-Mental Status Examina-
tion are used to describe the severity of dementia.
Patients are considered to be in mild stages of disease
when scoring 20 points or above, to be in moderate stages
of disease when scoring between 10 and 19, and severe
when scoring 9 or less.
Semantic fluency [18]
Assessment of the semantic fluency is a measure of exec-
utive functioning. It can be used to screen for cognitive
deficits [19] and was used in this study to assess proxies.
Behavioral pathology in Alzheimer's Disease Rating Scale 
(Behave-AD [20])
The Behave-AD is a clinical rating instrument to charac-
terize the phenomenology of behavioral symptoms. It
comprises 25 items, all of which are answered by the
proxy.
Geriatric Depression Scale (GDS [21])
The Geriatric Depression scale uses a 15-item question-
naire to assess symptoms of depression and has been vali-
dated in cognitively intact and demented elderly [22,23].
Activities of Daily living (Bayer-ADL [24])
This scale is used to assess the deficits in the performance
of the patients' everyday activities. It comprises 25 items,
all of which are answered by the proxy. Ratings are made
on a 10-point Likert-type scale.
Euro-QoL (EQ-5D [25])
The EQ-5D questionnaire is a generic instrument to mea-
sure health related QoL in five domains: mobility , self-
care, usual activities, pain/discomfort and anxiety/
depression. It can be applied to patients as well as used in
proxies to rate their own and the patients' QoL [26,27].
There are two core components of this instrument: a
description of the respondents own health in the above
mentioned five domains (rated on a three point Likert
scale each) and a rating of the overall own health on a
visual analog scale (VAS, score 0 - 100). For the present
study the VAS was not analyzed. In order to capture the
cognitive deterioration, a cognitive dimension was added
(EQ-5D + C). This allows to calculate the scores for the
EQ-5D and te EQ-5D + c. In the present study both the
patient and the proxies completed the EQ-5D + C
(patient-self-rating and proxy-self-rating, respectively).
Additionally, the proxy was asked to rate the quality of life
of the patient: proxy-patient-rating. Since the interviews
were carried out separately, patients and the proxies had
no opportunity to distort rating by exchanging their
answers.
Data Analysis
All statistical analyses for the investigation of group dif-
ferences were carried out using the statistics program
SPSS (SPSS 15.0 for Windows, Chicago, Ill., 2001). The
normality of the distribution was tested with the Kolmog-
orov-Smirnov Test. As the data were not normally dis-
tributed we used the Wilcoxon-test and the Spearman's
correlation coefficient.
Results
Disease severity - cognition, mood, and activities of daily 
living
Commonly, the severity of dementia is grouped accord-
ing to the scores in the MMSE. Accordingly, we analyzed
the relation between quality of life assessments and the
severity of disease (mild: MMSE score ≥20; moderate: 10
≤ MMSE score ≤19; severe: 3 ≤ MMSE score ≤9). The
study included 51 patients with mild, 66 patients with
moderate and 20 patients with severe dementia.
Proxies of patient that are more severely affected report
more behavioral symptoms (BEHAVE-AD; p = 0.021) and
more impairment in activities of daily living (Bayer-ADL;
p < 0.001). Patients themselves, however, do not report an
increase of depressive symptoms (GDS; p = 0.985).
Disease severity and quality of life
Severity of dementia is not mirrored in the self-rating of
the quality of life of the patient and the self-rating of the
quality of life of the proxy. The results of the one-factorial
Kruskal-Wallis test for the self-rating of QoL of the
patient, the proxy-rating of the QoL of the patient, and
the proxy-patient-rating of the QoL for the EQ-5d and
the EQ-5d with additional cognitive domain are shown in
Table 2.
In the self-assessment of both the patient and the proxy
no differences were found in the EQ-5d or the EQ-5d
with additional cognitive domain. However, the proxy
Table 2: Dementia severity and patient self-rating of the quality of 
life, proxy self-rating of the quality of life, and proxy-rating of the 
patients' quality of life. 
EQ-5d EQ-5d + c
Proxy self-rating 0.414 0.392
Proxy rating of patient 0.002 0.001
Patient self-rating 0.148 0.088
p-values from Kruskal-Wallis test for comparison across mild, 
moderate, and severe dementia. EQ-5D: Euroqol. EQ-5D + C: EQ-5D 
plus cognitive domain.Schiffczyk et al. BMC Neurology 2010, 10:48
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assessment of the patients' quality of life decreased with
increasing severity of dementia of the patient.
Patient-rating and proxy-rating
In both the EQ-5d and the EQ-5d with supplemented
cognitive domain a discrepancy between the judgment of
the proxy and the judgment of the patient is observed
(Figure 1).
The difference between the patients estimation of QoL
and the proxie's estimation of the patient's QoL correlates
with the MMSE of the patient (Spearman's rho EQ-5d = -
0.434; rho EQ-5d + c = -0.444, respectively; p < 0.001
both). Even if the analysis is confined to patients with an
MMSE score of 20 and above the difference between the
patients estimation of QoL and the proxie's estimation of
the patient's QoL correlates with the MMSE of the
patient (Spearman's rho EQ-5d = -0.328 (p = 0.019); rho
EQ-5d + c = -0.347 (p = 0.012) (Figure 2).
Estimation of the patient's QoL by the proxy correlates
not only with patient-related parameters but also with the
GDS-score of the proxy (EQ-5d: Spearman's rho = 0.317,
p < 0.001; EQ-5d + c: rho = 0.336, p < 0.001) and cognitive
functions such as the semantic fluency (EQ-5d: Spear-
man's rho = 0.209, p < 0.018; EQ-5d + c: rho = 0.216, p <
0.014). Thus, proxies that are more depressed and/or
have better performance in the semantic fluency task
themselves rate the quality of life of the patient worse.
Discussion
With progressing severity of dementia cognitive abilities
of the patient, behavioral symptoms and activities of daily
living are impaired. This implies that the patient's auton-
omy is reduced. Neither is the patient able to uphold lei-
sure activities on his or her own nor is the patient able to
sustain functions to preserve living such as household
chores or food preparation without help. In the EQ-5d
two questions specifically ask for the ability to care for
oneself and everyday activities. Patients' interpretation
and self-rating of these questions, however, may deviate
from objective capturing of measures of these variables
and may be more subjectively interpreted to also depend
on other variables such as the burden of proxies resulting
in differences in the availability of care for the patient.
Therefore the term 'quality of life' may not mean the same
thing when patients and healthy persons talk about it.
Thus, the interpretation of 'quality of life' likely remains
ambiguous even when patients and proxies are asked the
same questions.
In contrast to previous investigations, the present study
was performed with visitation of patients and their prox-
ies in their household to catch their assessment in their
familiar environment. There are some possible limita-
tions to this approach. Although the participants were
recruited country-wide this cohort may represent a sub-
sample of the population as the proxies and patients were
recruited from a database of patients that had applied for
a short-term rehabilitation program in a specialized
dementia service (Alzheimer Therapy Center Bad Aib-
ling, Germany). In contrast to other studies, however,
assessment of the patients and proxies in their familiar
surroundings excludes distortion by being asked in a less
well known environment such as a medical office.
A lack of deterioration of quality of life assessment with
current instruments in more severe stages of disease was
interpreted in a way that the actual life's quality of the
patients does not deteriorate with severity of disease [12].
This rests on reports that the capability of self-assess-
ment of Qol is not impaired by the severity of cognitive
impairment [9,10,28]. Other studies, however, concluded
that the validity of self-reported QoL is uncertain in AD
[29-32] because patients in early stages of AD are likely to
give overly optimistic ratings of their capabilities and
activities [8]. The present study demonstrates that in
spite of deterioration of cognitive abilities, behavior, and
the impairment of daily functions an established instru-
ment to assess the quality of life does not pick up this loss
of function. The self-reported quality of life of patients
does not decrease in more severe stages of dementia. One
reason may be, that patients with dementia often have
decreased awareness of their cognitive impairments and
changes in behavior [8,33,34] which likely results from
affliction of brain regions partaking in awareness of func-
tional capacities with increasing severity of dementia
[35]. An alternative explanation is that patients with
dementia receiving support by caring proxies do not per-
ceive limitations in their life. However, this chain of
thought implicitly presumes the patient to be able to
value his or her situation and abilities. Applying Ock-
ham's principle of parsimony we conclude on neurobio-
logical grounds and the results of the present study with
patient's self-assessed quality of life scales not reflecting
obvious everyday impairments whatsoever and proxy-
assessment of the patient being dependent on proxies'
mood and cognitive abilities that QoL instruments are
useless in dementia research. The influencing variables
on the side of the proxy have far-reaching implications
considering the current discussion on advanced direc-
tives and end-of-life issues. When proxies are being asked
on end-of-life issues on behalf of the patient they may not
be able to capture the impact of disease on the patients'
lifes having the concept of 'quality of life' in mind. This
resembles the discussion in another neurodegenerative
disease, amyotrophic lateral sclerosis, where proxies may
draw other conclusions on life-sustaining treatment from
assessing the medical condition of the patient than
patients themselves [36].
One would expect that the quality of life of the proxy is
affected in more severe stages of dementia in the patientSchiffczyk et al. BMC Neurology 2010, 10:48
http://www.biomedcentral.com/1471-2377/10/48
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Figure 1 Scores in the A) Euroqol (EQ-5d; score range EQ-5d: 0 - 15) and the B) Euroqol with added cognitive domain (EQ-5d + c; score range 
EQ-5d + c: 0 - 18) for the patient self-rating (white bars) and the proxy-rating of the patient (black bars).Schiffczyk et al. BMC Neurology 2010, 10:48
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as the proxy has to compensate for the loss of function of
the patient. However, the present study shows that the
increased demand on the caregiver does not result in a
decreased quality of life in the self-assessment of the
proxy which is similar to a previous report [10]. This may
indeed reflect the successful adaptation of the caregiver
or successful use of coping strategies. Potentially this may
also indicate that a sizeable portion of proxies of demen-
tia patients suffer from cognitive problems or neuropsy-
chiatric disorders as well [37].
Other than the patients' self-assessment, the proxies'
assessment of the patients' quality of life is reduced with
increased dementia severity of the patient. In the present
study proxies rated the Qol of the patient worse than the
patient in both the conventional Euroqol as well as when
the score included an additional cognitive dimension
(EQ-5D + c). It has been reported, previously, that proxy-
ratings of Qol in AD patients do not correlate with the
patients' self-report [13,38,39]. The present study shows
that the discrepancy between self- and proxy rating of
QOL increases with severity of disease.
A previous study concluded that patient- and caregiver
report may both represent valid, although differing, per-
spectives on quality of life [14]. The present study, how-
e v e r ,  d e m o n s t r a t e s  t h a t  t h e  p r o x i e s '  a s s e s s m e n t  o f  t h e
patients' quality of life is not only related to the disease
process in the patient but to factors of the proxy such as
their mood and their own cognitive function. To further
clarify these issues it would be necessary to assess addi-
tional variables such as availability and use of social ser-
vices, day care centers, support groups, and also other
instruments to appraise burden of disease or impact of
disease. These were not included in the present study
because the availability of resources and living conditions
were anticipated to vary too much across the nationwide
recruitment area. Future research, however, should
address these issues.
Conclusions
We conclude that rating of the QoL with the Euroqol is a
useless measure in dementia research. Patients' and prox-
ies' self-assessment of their own QoL does not reflect
severity of disease. Proxies' assessment of the patients'
QoL is related to the proxies' health, and the difference of
patient's and proxie's QoL-ratings is correlated with
dementia severity even in mild dementia stages (MMSE
equal or above 20). Thus, patients' and proxies' influenc-
ing variables render the score obtained with generic qual-
ity of life assessment meaningless in capturing the impact
of dementia. Therefore, decisions on initiation or discon-
Figure 2 Difference of the proxy-rating of the patients' quality of life and the patient self-rating for the EQ-5d (black dots; score range EQ-
5d: 0 - 15) and the EQ-5d + c (white squares; score range EQ-5d + c: 0 - 18) against the MMSE score (score range MMSE: 0 - 30).Schiffczyk et al. BMC Neurology 2010, 10:48
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tinuation of treatment or allocation of other resources for
patients with dementia therefore need not depend on
generic assessment of quality of life.
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